Trial Profile
A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, and Efficacy of AVP-786 for the Treatment of Disinhibition in Patients With Neurodegenerative Disorders
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 27 Oct 2020
Price :
$35
*
At a glance
- Drugs Deudextromethorphan (Primary)
- Indications Dementia; Neurodegenerative disorders
- Focus Therapeutic Use
- Sponsors Avanir Pharmaceuticals
- 19 Jan 2018 Status changed from recruiting to discontinued.
- 13 Feb 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Dec 2017.
- 11 Jul 2016 Planned End Date changed from 1 Mar 2017 to 1 Mar 2018.